Lentiviral Vectors as a Vaccine Platform against Infectious Diseases - Institut Pasteur Access content directly
Journal Articles Pharmaceutics Year : 2023

Lentiviral Vectors as a Vaccine Platform against Infectious Diseases

Abstract

Lentiviral vectors are among the most effective viral vectors for vaccination. In clear contrast to the reference adenoviral vectors, lentiviral vectors have a high potential for transducing dendritic cells in vivo. Within these cells, which are the most efficient at activating naive T cells, lentiviral vectors induce endogenous expression of transgenic antigens that directly access antigen presentation pathways without the need for external antigen capture or cross-presentation. Lentiviral vectors induce strong, robust, and long-lasting humoral, CD8+ T-cell immunity and effective protection against several infectious diseases. There is no pre-existing immunity to lentiviral vectors in the human population and the very low pro-inflammatory properties of these vectors pave the way for their use in mucosal vaccination. In this review, we have mainly summarized the immunological aspects of lentiviral vectors, their recent optimization to induce CD4+ T cells, and our recent data on lentiviral vector-based vaccination in preclinical models, including prophylaxis against flaviviruses, SARS-CoV-2, and Mycobacterium tuberculosis.
Fichier principal
Vignette du fichier
pharmaceutics-15-00846-with-cover.pdf (1.25 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

pasteur-04087457 , version 1 (03-05-2023)

Licence

Attribution

Identifiers

Cite

Kirill Nemirov, Maryline Bourgine, François Anna, Yu Wei, Pierre Charneau, et al.. Lentiviral Vectors as a Vaccine Platform against Infectious Diseases. Pharmaceutics, 2023, 15 (3), pp.846. ⟨10.3390/pharmaceutics15030846⟩. ⟨pasteur-04087457⟩

Collections

PASTEUR
11 View
46 Download

Altmetric

Share

Gmail Facebook X LinkedIn More